85.941 IDD Coordinated Care The Medical Society of the State of New York (MSSNY) will create a policy pertaining to the development of a comprehensive program to provide coordinated health, dental, vision, behavioral health, and social services to the IDD population. MSSNY will adopt as its policy position that the society shall work with all
75.970 Patient Medication Safety The Medical Society of the State of New York will continue to advocate together with the American Medical Association in support of efforts to ensure that the FDA has all the resources necessary to perform necessary inspection and testing of the manufacturing of medications, as well as preventing against drug shortages.
75.969 Medicare Coverage of OTC Nicotine Replacement Therapy MSSNY will advocate for OTC nicotine replacement therapies, excluding vaping products, to be carved out from the non-coverage by Medicare of OTC products and be specifically covered when prescribed by physicians who care for patients with Medicare, Medicare Part D, or Medicare Part C coverage. MSSNY will
75.968 Medication Not Approved by FDA For Use in Humans The Medical Society of the State of New York (MSSNY) will advocate for New York State legislation stating that insurance companies and other related entities must never be required to pay for substances not approved by FDA for use in humans. MSSNY will urge the
75.967 Appropriate Warning Labels and Signs for Vape and Marijuana MSSNY will advocate for clear and legible warnings on products containing THC and/or nicotine regardless of the vehicle in which they are contained. MSSNY will also advocate for clear, legible warning signs to be posted in businesses that sell products containing THC and/or nicotine. (HOD
75.966 Medical Use of Psilocybin and 3, 4-Methylenedioxymethamphetamine (MDMA) MSSNY awaits FDA evaluation of psilocybin and MDMA clinical trials completed and underway so that scientific data informs judgments about risks and benefits of treatment. MSSNY will advocate that New York State wait for the FDA to approve psilocybin and MDMA as safe medications with guidance
75.965 Rapid Response to Medication and Device Shortages The Medical Society of the State of New York will provide information on the MSSNY website on how to report drug shortages to the Food and Drug Administration. MSSNY will work with the American Medical Association on its efforts to help mitigate drug Shortages, and these efforts
70.925 Mandating Child-proof Packaging on Marijuana Products Sold Legally in New York State The Medical Society of the State of New York will advocate for legislation or regulation mandating all cannabinoid products sold legally by licensed marijuana dispensaries in the State of New York to be sold to consumers in child-resistant packaging. (HOD 2023-154)
70.924 Methadone as Medication for Opioid Use Disorder in Community Settings MSSNY will support pilot projects on expansion of office-based methadone treatment for OUD outside OTPs when prescribed by addiction specialists and dispensed at local pharmacies with appropriate training and safeguards in place. (HOD 2023-155)
70.923 Retire Current NYS I-STOP Prescription Drug Monitoring Program and Transition to the Multistate PMP System The Medical Society of the State of New York will advocate to the New York State Department of Health for full integration access to multistate database in New York State Prescription Monitoring Program (PMP). MSSNY will also advocate for
